Stock Analiz10x Genomics, Inc. TXG
Biotechnology: Laboratory Analytical Instruments · IPO 2019 · data as of November 13, 2026
10x Genomics, Inc. (TXG) is a industrial company listed in the US with a market value of about $7.7B. In the twelve months to September 30, 2026 it had revenue of $619M and net income of -$67M, a net margin of -10.8%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 81.6, 5-year revenue growth of 17% a year, a 5-year average ROIC of -14%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 95% below the current price.
Score: 1.4 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $619M | $643M | $611M | $619M | $516M | $490M | $299M | $246M | $146M | $71M |
| Net income | -$67M | -$44M | -$183M | -$255M | -$166M | -$58M | -$543M | -$31M | -$112M | -$19M |
| Free cash flow | $94M | $130M | -$6M | -$64M | -$165M | -$123M | -$255M | -$8M | -$83M | -$14M |
| EPS (diluted) | $-0.52 | $-0.35 | $-1.52 | $-2.18 | $-1.46 | $-0.53 | $-5.37 | $-0.80 | $-8.40 | $-1.62 |
| Net margin | -10.8% | -6.8% | -29.9% | -41.2% | -32.1% | -11.9% | -181.6% | -12.7% | -76.9% | -26.4% |
| ROIC | — | -5.5% | -19.4% | -25.1% | -14.7% | -4.6% | -52.6% | -4.8% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $68.14, 17% above the current price; targets range from $50.00 to $100.00; the consensus rating is “Buy”; expected EPS is $0.06 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is 10x Genomics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 95% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does 10x Genomics pay a dividend?
Not currently.
Is 10x Genomics a good stock to buy?
We do not give buy or sell advice. 10x Genomics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.